27 results about "Coagulopathy" patented technology

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention discloses a sepsis clotting disease subtype characteristic and typing system, which comprises a basic data acquisition module used for acquiring SIC patient characteristics; a potential category analysis module configured to identify potential groups of the SIC patients based on the SIC patient features; the K-means clustering module is configured to cluster the characteristics of the SIC patients and obtain a clustering result of the SIC patients; and the typing result output module is configured to output subtype features and typing results of the SIC patients based on the potential groups of the SIC patients and the clustering results of the SIC patients. The subtype classification of the SIC patient can be rapidly and accurately analyzed, and a direction is provided for subsequent treatment.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

In some embodiments provided herein is a method of treating a coagulopathy in a subject, the method including administering to the subject in need thereof an effective amount of a composition including platelets or platelet derivatives and an incubating agent including one or more salts, a buffer, optionally a cryoprotectant, and optionally an organic solvent, wherein the subject has been treated or is being treated with an antiplatelet agent.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

Methods of treating coagulopathy using a bispecific antibody comprising (i) a first antigen-binding site capable of binding Factor Vll(a), and (ii) a second antigen-binding site capable of binding TREM-like Transcript 1 (TLT-1).

A coagulation test device for measuring clot time and clot characteristics of whole blood samples under different hemostatic conditions. The test results are used as an aid in the management of patients with unexplained coagulopathy for the purpose of helping the physician to determine appropriate clinical measures to hemostasis in the patient.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

The application belongs to the technical field of biological medicine, and particularly relates to application of a detection LGALS2 gene reagent in preparation of a reagent kit for detecting sepsis coagulopathy. The product diagnoses sepsis coagulopathy by detecting the transcription level of the LGALS2 gene in a sample, and when the transcription level of the LGALS2 gene is significantly reduced, the subject has sepsis coagulopathy. The application uses LGALS2 as a biomarker, and through a human experiment verification, the transcription level of peripheral blood LGALS2 of a sepsis coagulopathy patient is significantly lower than that of a patient without sepsis coagulopathy. The transcription level of LGALS2 in whole blood RNA has high specificity and sensitivity in diagnosis and prediction of the risk of sepsis coagulopathy. The LGALS2 gene and the transcription level thereof can be used for preparation of a reagent or a kit for early diagnosis of sepsis coagulopathy, provide reference information for giving individualized intervention treatment, and have important clinical application value and popularization.

The invention pertains to a therapeutic formulation, CARDIOGARDIA, for the management of cardiac arrest. The formulation co-formulates selected microRNAs, including miR-21, miR-1, miR-29, miR-17, and miR-133, and antithrombin and essential electrolytes in a single formulation. The different components in combination target various pathological processes associated with cardiac arrest, including fibrosis, apoptosis, arrhythmia, and coagulopathy. Delivery may be affected by suitable pharmaceutical vehicles or carriers to enable effective delivery. By acting on these distinct pathological processes in combination, the formulation provides a multifaceted approach to stabilizing cardiac function and improving resuscitation outcome. The invention further encompasses methods of treating subjects experiencing cardiac arrest by administering the formulation in therapeutically effective amounts.

This invention relates to a wholly recombinant four factor hemostatic complex concentrate (4F-PCC) composition, human liver cell-produced product. Methods of producing a hemostatic composition using a hepatocyte cell line and a CRISPR / Cas9 gene activation multiplexing, which allows for simultaneous and high level expression of the FII, FVII, FIX, and FX clotting factors. The resultant product is a recombinant resuscitation solution to aid in mitigation of coagulopathy, reversal of coagulopathic states, and fluid resuscitation.

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

The present invention relates to bispecific antibodies capable of binding to coagulation Factor IX (FIX) and / or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and / or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A with or without inhibitors.

A device for performing coagulation tests that measure clotting time and clot characteristics in a whole blood sample under different hemostatic conditions. The test results are used to aid in the management of patients with coagulopathy of unknown etiology, helping the physician determine the appropriate clinical action to stop bleeding.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a reagent for detecting an LGALS2 gene in preparation of a kit for detecting sepsis coagulopathy. According to the product, the sepsis coagulopathy is diagnosed by detecting the transcriptional level of the LGALS2 gene in a sample, and when the transcriptional level of the LGALS2 gene is remarkably reduced, a subject suffers from the sepsis coagulopathy. According to the application disclosed by the invention, LGALS2 is adopted as a biomarker, and the transcriptional level of LGALS2 in peripheral blood of a patient suffering from sepsis coagulopathy is obviously lower than that of a patient not suffering from sepsis coagulopathy through crowd experiments. The transcriptional level of the LGALS2 in the whole blood RNA has high specificity and sensitivity on diagnosis and prediction of the generation risk of sepsis coagulopathy. The LGALS2 gene and the transcriptional level thereof can be used for preparing a reagent or a kit for early diagnosis of sepsis coagulopathy, reference information is provided for individualized intervention treatment, and the LGALS2 gene has important clinical application value and generalization performance.

The present invention relates to bispecific antibodies that can bind to coagulation factor IX (FIX) and / or its activated form factor IXa (FIXa) and factor X (FX) and / or its activated form factor Xa (FXa) and promote the activation of FX by FIXa, as well as methods and compositions for treating subjects suffering from coagulopathy such as hemophilia A with or without inhibitors.

The invention relates to the technical field of auxiliary hemostasis devices, and discloses an emergency auxiliary hemostasis device for a blood coagulation dysfunction patient, which comprises a fixing plate I, a drug delivery mechanism arranged on the inner side of the fixing plate I, a compression mechanism arranged at the bottom of the fixing plate I, and a fixing mechanism arranged on the inner side of the fixing plate I, the fixing mechanism is arranged at the bottom of the first fixing plate, and the dosing mechanism comprises a hemostasis assembly. According to the hemostasis device, the hemostasis assembly is arranged, specifically, when a rotating sleeve rotates, a rotating ring is driven to rotate, a first sliding rod at the bottom of the rotating sleeve slides in a sliding groove, a sliding plate is pushed to be separated towards the two sides along a sliding rail, a second fixing plate extrudes a telescopic rod and a first spring, medicine in a fixing sleeve is released, and after releasing is completed, the rotating sleeve is loosened; under the elastic reset action of the telescopic rod and the first spring, the second fixing plate and the sliding plate are close to each other, the bottom of the fixing sleeve is closed, the utilization efficiency of hemostatic medicine is improved, and a hemostatic environment is rapidly formed.

The present disclosure provides combinations of tissue plasminogen activator mutant / s and lysine analogs and compositions thereof for inhibiting fibrinolysis induced by free plasmin. The present disclosure further provides kits, uses and methods for treating coagulopathy associated with anti-fibrinolytic therapy.

A handheld medical analyzer works with different disposable application cartridges to perform a variety of interrogations on specimen samples. One application includes attaching a biological microelectromechanical systems (BioMEMS) cartridge that generates blood coagulation profiles indicative of particular forms of coagulation disorders. The device makes coagulopathy testing simpler for small hospitals, clinics, ambulances, remote locations and individuals and permits for a larger number of parallel or serial devices operating simultaneously. One insertion of a cartridge actuates an oscillating circular motion to generate a blood coagulation profile based on a change in rotational motion as blood coagulates in a sample. Change in rotational motion is analyzed through a video camera such as in a smartphone and is plotted to show an amplitude over time. Actuation of the BioMEMS can be achieved by magnetic actuation of a motor controlled by an iPhone or a smart phone to provide a specific rotational pattern.

Bio-artificial blood substitutes are provided for intravenous medical use to restore or increase tissue perfusion and oxygen delivery in a pre-hospital or hospital setting. The bio-artificial blood substitutes comprise three modular components (polyethylene glycol (PEG) polymers to increase perfusion, a hemoglobin-based oxygen carrier (HBOC) plus L-arginine to prove oxygen carrying capacity, and a lyophilized fibrinogen or plasma component to provide hemostasis potential, all of which are administered sequentially in modules to treat low perfusion states with possible coagulopathy as seen in blood loss and shock. The three solutions are stable at ambient temperature and are well-suited for use in the field, e.g., when immediate, critical care is needed such as on the battlefield, during natural disasters or other mass casualty events. Other use may include clinical need for transfusion or for peri-surgical resuscitation in patients unable to receive standard blood products.

Novel methods for preventing, reducing the risk of development of, and for treating hypercoagulopathy in Cushing's syndrome patients with elevated risk of developing hypercoagulopathy are disclosed. The methods are further useful to prevent, to reduce the risk of developing, and to treat deep vein thrombosis (DVT), pulmonary embolism (PE), and venous thromboembolism (VTE); and to treat inflammatory states.The methods include: administering heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator (HKGRM) to a Cushing's syndrome patient at risk of developing hypercoagulopathy, thereby treating hypercoagulopathy. Methods of preventing, reducing risk of developing, and of treating DVT, PR, or VTE in a Cushing's syndrome patient comprise administering a HKGRM to the patient. Methods of unmasking and subsequently reducing an inflammatory state comprise administering an effective amount of a HKGRM to a Cushing's syndrome patient, effective first to increase inflammatory symptoms and then to subsequently decrease said inflammatory symptoms in the patient.

Methods of treating coagulopathy using a bispecific antibody comprising (i) a first antigen-binding site capable of binding Factor Vll(a), and (ii) a second antigen-binding site capable of binding TREM-like Transcript 1 (TLT-1).

Clinically validated methods of administering Yunnan Baiyao or Xingnaojing can improve postoperative recovery and long-term clinical prognosis of patients with moderate-to-severe traumatic brain injury (TBI) and emergency craniotomy. Both medicinal methods are useful for minimizing or inhibiting the adverse impacts of secondary injury, oxidative damage and neuroinflammation associated with TBI, spinal cord injury, craniotomy / craniectomy, cerebral hemostasis and hemorrhage, coagulopathy, stroke, neural injury and neuroinflammation, and for promoting the long-term functional recovery and well-being of the patients with the afore-mentioned diseases.

A use of a S protein or P4HB protein as a target in preparation of a drug for prevention or treatment of coagulopathy associated with SARS-CoV-2 infection. The S protein is the spike protein of SARS-CoV-2 virus, and the P4HB protein is human protein disulfide isomerase. By means of integrated proteomic and bioinformatic study on SARS-CoV-2 interaction networks in endothelial cells, pulmonary cells, and bronchial cells, the S protein is determined as a key contributor to the procoagulant characteristics of viruses, and the S protein plays a critical role in inducing endothelial cell dysfunction. The S protein directly interacts with P4HB by means of an RBM region thereof, and promotes the secretion of P4HB by means of a lysosomal secretion pathway, thereby promoting thrombosis both in vitro and in a mouse model. Genetic or pharmacological targeting of S-P4HB axis can alleviate coagulopathy in a mouse model. The level of P4HB and disulfide bonds of target proteins thereof are significantly altered in the plasma and leukocytes of COVID-19 patients and are closely associated with the disease severity and coagulation correlation of these patients.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent related to generation and development of sepsis-related blood coagulation diseases and application of the reagent. When the CD10-containing reagent is used for detecting the sepsis-related coagulopathy, the detection comprises the following steps: S1, collecting peripheral blood of a sepsis patient, and storing the peripheral blood for later use; s2, carrying out grouping on the neutrophile granulocytes by adopting CD45, CD15 and CD66b, and detecting the immunophenotypes of the neutrophile granulocytes by adopting CD10; adding an Fc blocking antibody into the collected peripheral blood according to the ratio of 1: 100; preparing an antibody premixed solution, and adding the antibody premixed solution for dyeing after the closing is finished; s3, diluting the erythrocyte lysate to a working concentration; the working solution is added into the dyed peripheral blood for red cracking, and after red cracking is finished, a PBS solution is added; performing centrifugal treatment to obtain single-cell precipitate and supernate; s4, removing the supernate, and repeating the step S3; adding a PBS (Phosphate Buffer Solution) for resuspending to obtain a colorless clear transparent single-cell suspension, carrying out flow-type on-machine detection on the single-cell suspension, and calculating the proportion of mature neutrophils to immature neutrophils.